Loading...

SEPN SEPTERNA INC US FDA Inspections 8-K Filing

SPTR

SPN

SEPTERNA INC

(SEPN)

2025 8-K

Show Summary

Summary

Investor Presentation Update

Clinical Trial Announcement

Financial Statements

Financial Results

Investor Meetings

Trial Discontinuation

Investor Conference

CFO Appointment

Financial Results

Incorporation Changes

External Links:

On August 21, 2025, Septerna, Inc. announced the dosing of the first participants in a Phase 1 clinical trial for SEP-631, aimed at treating mast cell-driven diseases.

AI Assistant

SEPTERNA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.